Why Pfizer’s R&D Chief Dolsten Is Enthusiastic About Allergan
This article was originally published in The Pink Sheet Daily
Executive Summary
President-Worldwide R&D Mikael Dolsten talked in an interview at J.P. Morgan about the research opportunities for a combined Pfizer/Allergan – and bridging two different approaches to R&D.